Precision Cancer Prevention and Treatment: Leveraging Innovations in Molecular Medicine to Improve Early Detection, Prevent Recurrence and Optimize Outcome

This in-person only*, full-day joint symposium, dedicated to Precision Cancer Prevention and Treatment, features international-recognized faculty and opinion leaders from Memorial Sloan Kettering and Hackensack Meridian Health. Molecular innovations will be highlighted, including how these can be applied across the care continuum and integrated with clinicopathologic and lifestyle factors to prevent cancer in the broadest sense:

• by facilitating earlier diagnosis at a more treatable stage;
• guiding risk stratification; and
• preventing relapse through early and targeted precision interventions for molecularly-identified, minimal residual disease.

There will be keynotes, lectures and panel discussions engaging on topics that include disease prevention at the molecular level, immunobiomarkers, liquid biopsies in oncology, parallel tumor normal sequencing to inform diagnosis and management, molecular medicine and diverse populations, using “big-data” studies to better understand the impact of molecular medicine, and the medical implications of clonal hematopoiesis of indeterminant potential. There will be ample opportunity to interact with program faculty and attendees.

Who Should Attend

This symposium is intended for physicians, advanced practice providers, nurses, researchers, and trainees interested in molecular medicine, precision cancer prevention, and targeted treatments.

Symposium Location

This symposium is hosted by the Memorial Sloan Kettering - Hackensack Meridian Health Partnership will be held at the Hackensack Meridian Health School of Medicine.

Hackensack Meridian Health School of Medicine
123 Metro Boulevard
Nutley, NJ 07110
Get directions

Please note that this course will only be offered as a live in-person option; no live stream or recording will be available.

1. To appreciate how molecular data can be used to inform risk and guide interventions to prevent disease and improve outcomes.
2. To understand the potential utility and limitations of liquid biopsies.
3. To understand how germline data can complement tumor sequencing in cancer management.
4. To learn how molecular data can complement healthy living programs.
5. To understand what clonal hematopoiesis of indeterminant potential is and its medical implications.
6. To appreciate how “big data” studies can be used to assess the impact of molecular medicine.

Registration Fees*

• Residents, Fellows, and Trainees: $25
• All Other Healthcare Providers: $75 

*Please note this MSK CME event is non-refundable.

Discounts/Promotions

• A registration discount is available for MSK Alumni, and MSK Cancer Alliance to attend a MSK CME course. If you are a member of one of these groups, contact [email protected] for details.
• Registration is complimentary for all Hackensack Meridian Health employees, however, you must complete registration through this website in order to attend. If you have not received a promotion code for complimentary registration, please contact [email protected].  If you are registered for this course and are unable to attend, please notify [email protected].
• Registration is complimentary for all MSK employees; however, you must complete registration through this website in order to attend. If you are registered for this course and are unable to attend, please notify [email protected].

Please note that after your payment has been processed, no further promotional discounts or adjustments will be made to your registration.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Memorial Sloan Kettering Cancer Center and Hackensack Meridian Health. Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of 4.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MSK-HMH Partnership Executive Leaders

Andre Goy, MD
Physician-in-Chief, Hackensack Meridian Health 
Oncology Care Transformation Services; 
Chairman & Chief Physician Officer, John Theurer Cancer Center at Hackensack University Medical Center; 
Lymphoma Division Chief, John Theurer Cancer Center

David Pfister, MD
Chief, Head and Neck Oncology Service; Associate Deputy Physician-in-Chief, Strategic Partnerships
Memorial Sloan Kettering Cancer Center

Guest Faculty

Maher Albitar, MD
Chief Executive Officer;
Chief Medical Officer Genomic Testing Cooperative
Irvine, CA

John Marshall, MD
Chief, Hematology and Oncology; 
Professor of Medicine and Oncology; 
Director, Otto J Ruesch Center for the Cure of Gastrointestinal Cancers
Georgetown Lombardi Comprehensive Cancer Center
Washington DC

Patient Speaker

Renee Al-Sarraf, DVM

Hackensack Meridian Health Faculty 

David (Kar Fai) Chow, MD
Medical Director, HMH Biorepository

Martin Gutierrez, MD
Director, Drug Discovery; 
Chief, Thoracic Oncology

Andrew Ip, MD
Director, Division of Outcomes and Value Research

Jamie Koprivnikar, MD
Attending, Hematology Oncology

David C. Leopold, MD, DABFM, DABOIM
Medical Director, Integrative Health and Medicine

Kash Patel, MD
Executive Vice President, Chief Digital Information Officer

Helio Pedro, MD
Section Chief, Genetic and Genomic Medicine

MSK Faculty

Andrea Cercek, MD
Section Head, Colorectal Cancer; 
Co-Director, Center for Young Onset Colorectal and Gastrointestinal Cancers

Luis Diaz Jr., MD
Head, Division of Solid Tumor Oncology; 
Grayer Family Chair

Neil Iyengar, MD
Medical Oncologist, Exercise Oncology

Ross Levine, MD
Chair, Leukemia Research; 
Chief, Molecular Cancer Medicine Service; 
Deputy Physician-in-Chief, Translational Research

Pedram Razavi, MD
Director of Liquid Biopsy Technologies and Genomics

Greg Riely, MD
Vice Chair of Clinical Research, Department of Medicine

Zsofia Stadler, MD
Clinical Director, Clinical Genetics Service

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.

Friday, November 4, 2022